{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:59:43Z","timestamp":1793923183542,"version":"4.8.0"},"reference-count":47,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>We investigated the impact of sarcopenia on adjuvant chemotherapy dosing in advanced epithelial ovarian cancer (EOC). The chemotherapy dosing and toxicity of 173 eligible patients who underwent cytoreductive surgery and adjuvant chemotherapy at a single institution were analyzed. Patients with a skeletal muscle index less than 39 cm2\/m2 measured on a CT scan were considered sarcopenic. Sarcopenic and non-sarcopenic patients were compared with regard to relative dose intensity (RDI), completion of scheduled chemotherapy, toxicity, and survival. A total of 62 (35.8%) women were sarcopenic. Sarcopenic women were less likely to complete at least six cycles of chemotherapy (83.9% vs. 95.5%, p = 0.02). The mean RDI for both carboplatin (80.4% vs. 89.4%, p = 0.03) and paclitaxel (91.9% vs. 104.1%, p = 0.03) was lower in sarcopenic patients compared to non-sarcopenic patients. Despite these differences in chemotherapy, there was no difference in neutropenia or median overall survival (3.99 vs. 4.57 years, p = 0.62) between the sarcopenic and non-sarcopenic women, respectively. This study highlights the importance of considering lean body mass instead of body weight or surface area in chemotherapy dosing formulas for sarcopenic women with advanced EOC. Further research is needed to optimize chemotherapy strategies based on individual body composition, potentially leading to improved dosing strategies in this population.<\/jats:p>","DOI":"10.3390\/curroncol30110688","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:18:52Z","timestamp":1698405532000},"page":"9501-9513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia"],"prefix":"10.3390","volume":"30","author":[{"given":"Rushi","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Polen-De","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Summa Health, Akron, OH 44304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"McGree","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Division Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fought","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Division Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1470-1305","authenticated-orcid":false,"given":"Amanika","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecological Surgery, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13539-010-0014-2","article-title":"An overview of sarcopenia: Facts and numbers on prevalence and clinical impact","volume":"1","author":"Morley","year":"2010","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_5","first-page":"177","article-title":"Clinical definition of sarcopenia","volume":"11","author":"Santilli","year":"2014","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TA.0000000000001657","article-title":"Sarcopenia increases risk of long-term mortality in elderly patients undergoing emergency abdominal surgery","volume":"83","author":"Rangel","year":"2017","journal-title":"J. Trauma Acute Care Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jso.24025","article-title":"The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature","volume":"112","author":"Joglekar","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jamaoncol.2018.0137","article-title":"Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer","volume":"4","author":"Caan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/JTO.0000000000000690","article-title":"Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer","volume":"10","author":"Kim","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Fukushima, H., Yokoyama, M., Nakanishi, Y., Tobisu, K., and Koga, F. (2015). Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0115895"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lee, J.S., Kim, Y.S., Kim, E.Y., and Jin, W. (2018). Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202700"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-017-3395-5","article-title":"Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers","volume":"80","author":"Yoshikawa","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jcsm.12107","article-title":"Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients","volume":"7","author":"Rutten","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/IGC.0000000000000867","article-title":"Sarcopenia in Advanced Serous Ovarian Cancer","volume":"27","author":"Bronger","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejso.2016.12.016","article-title":"The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery","volume":"43","author":"Rutten","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","year":"2001","journal-title":"Investig. New Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-008-0856-x","article-title":"Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?","volume":"64","author":"Ekhart","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"676.e1","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: A nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ygyno.2020.05.046","article-title":"Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer","volume":"158","author":"Narasimhulu","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/BF01218365","article-title":"The use of the Calvert formula to determine the optimal carboplatin dosage","volume":"121","author":"Rodenhuis","year":"1995","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jcsm.12468","article-title":"Sarcopenia and ovarian cancer survival: A systematic review and meta-analysis","volume":"10","author":"Ubachs","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejso.2014.11.040","article-title":"Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer","volume":"41","author":"Tan","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5230\/jgc.2017.17.e8","article-title":"Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer","volume":"17","author":"Palmela","year":"2017","journal-title":"J. Gastric. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/1078-0432.CCR-16-0940","article-title":"Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy","volume":"23","author":"Shachar","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","article-title":"Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer","volume":"34","author":"Versteeg","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.clnu.2015.08.005","article-title":"The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma","volume":"35","author":"Rollins","year":"2016","journal-title":"Clin. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00330-014-3110-4","article-title":"Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer","volume":"24","author":"Yip","year":"2014","journal-title":"Eur. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"Prado","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1139\/apnm-2013-0403","article-title":"The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer","volume":"39","author":"Prado","year":"2014","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S0029665118000046","article-title":"A window beneath the skin: How computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes","volume":"77","author":"Daly","year":"2018","journal-title":"Proc. Nutr. Soc."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mir, O., Coriat, R., Blanchet, B., Durand, J.P., Boudou-Rouquette, P., Michels, J., Ropert, S., Vidal, M., Pol, S., and Chaussade, S. (2012). Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037563"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1210\/jc.2013-1115","article-title":"Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: Results from a placebo-controlled study","volume":"98","author":"Massicotte","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1586\/14737140.2013.866040","article-title":"Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma","volume":"14","author":"Antoun","year":"2014","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0305-7372(85)90027-1","article-title":"Carboplatin: The clinical spectrum to date","volume":"12","author":"Canetta","year":"1985","journal-title":"Cancer Treat. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0959-8049(93)90169-G","article-title":"The impact of received dose intensity on the outcome of advanced ovarian cancer","volume":"29","author":"Repetto","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2011.05.023","article-title":"Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer","volume":"122","author":"Fauci","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/bjs.9893","article-title":"Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies","volume":"102","author":"Levolger","year":"2015","journal-title":"Br. J. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2016.05.027","article-title":"Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer","volume":"142","author":"Kumar","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/ijgc-2022-003387","article-title":"Quality is more important than quantity: Pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer","volume":"32","author":"Fadadu","year":"2022","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:12:40Z","timestamp":1760130760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["curroncol30110688"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30110688","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}